Disclaimer: All content on this page is for educational and research purposes only. These compounds are research chemicals and are not FDA-approved for human use. Nothing here is medical advice — always consult a licensed medical provider before beginning any protocol.
Section 1 — Metabolic & Weight Management
Semaglutide — GS-10 (10mg vial)
| Class | GLP-1 receptor agonist |
| Reconstitution | Add 2 mL bacteriostatic water → 5,000 mcg/mL |
| Research Dose | 250 mcg–2.4 mg/week |
| Protocol | Weekly SubQ; titrate up over 4–12 weeks |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Research focuses on glucose regulation and appetite suppression. Titration is critical to GI tolerance. |
Tirzepatide — GT-10 / GT-30 / TZ-60 (10mg / 30mg / 60mg vials)
| Class | GIP/GLP-1 dual agonist |
| Reconstitution | GT-10: Add 2 mL BAC water → 5 mg/mL · GT-30: Add 3 mL → 10 mg/mL · TZ-60: Add 6 mL → 10 mg/mL |
| Research Dose | 2.5–15 mg/week |
| Protocol | Weekly SubQ; titrate over 4–20 weeks |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Dual-agonism provides additive GLP-1 + GIP signaling. Slower titration reduces nausea risk vs. single-agonist agents. |
Retatrutide — GR-10 / GR-20 / GR-30 / GR-40 (10–40mg vials)
| Class | GLP-1 / GIP / Glucagon triple agonist |
| Reconstitution | Add 2 mL BAC water per 10mg → 5 mg/mL |
| Research Dose | 1–12 mg/week |
| Protocol | Weekly SubQ; very gradual titration recommended |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Third-generation GLP class. Glucagon component adds thermogenic and hepatic metabolic effects not seen in dual agonists. |
Cagrilintide — CAG-5 (5mg vial)
| Class | Long-acting amylin analog |
| Reconstitution | Add 1 mL BAC water → 5 mg/mL |
| Research Dose | 0.16–4.5 mg/week |
| Protocol | Weekly SubQ; often studied alongside semaglutide (CagriSema protocol) |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Amylin signaling slows gastric emptying and reduces food intake independently of GLP-1 pathway. |
AOD-9604 — AOD-10 (10mg vial)
| Class | Modified hGH fragment |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 250–500 mcg/day |
| Protocol | Daily SubQ; fasted state preferred; 12–16 week cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Lipolytic activity without IGF-1 stimulation. Research distinguishes it from full hGH for metabolic-only protocols. |
Fragment 176-191 — FR-176
| Class | C-terminal hGH fragment |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 250–500 mcg/day, split across 2 injections |
| Protocol | 1–2x daily SubQ; fasted AM and pre-bed; 8–12 week cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Similar mechanism to AOD-9604; targets fat cell beta-3 adrenoreceptors without affecting blood glucose in research models. |
Section 2 — GH Axis & Performance
Sermorelin — SRM-5 (5mg vial)
| Class | GHRH analog (29 amino acids) |
| Reconstitution | Add 2.5 mL BAC water → 2,000 mcg/mL |
| Research Dose | 200–500 mcg/injection |
| Protocol | Daily SubQ before bed; or 5 days on / 2 days off; 3–6 month cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Stimulates endogenous GH release via pituitary GHRH receptors. Preserves natural pulsatile GH pattern in research. |
CJC-1295 / Ipamorelin Blend — CJI-10 (10mg vial: 5mg CJC + 5mg Ipamorelin)
| Class | GHRH analog + selective GHRP combo |
| Reconstitution | Add 2 mL BAC water → 5 mg/mL total blend |
| Research Dose | 100–300 mcg per peptide per injection |
| Protocol | 2–3x daily SubQ; pre-bed + fasted AM; 5 on / 2 off |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Synergistic GHRH + GHRP signaling. Ipamorelin’s selectivity minimizes cortisol/prolactin side effects vs. first-gen GHRPs. |
GHRP-2 — G2-10 (10mg vial)
| Class | Second-generation GHRP; synthetic hexapeptide |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 100–300 mcg/injection |
| Protocol | 2–3x daily SubQ; fasted preferred; 8–12 week cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Strong GH pulse inducer via ghrelin receptor. May modestly elevate cortisol and prolactin at upper dose ranges in research. |
GHRP-6 — G6-10 (10mg vial)
| Class | First-generation GHRP; synthetic hexapeptide |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 100–300 mcg/injection |
| Protocol | 2–3x daily SubQ; fasted preferred |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Potent appetite stimulation is a well-documented effect in research. Commonly stacked with GHRH analogs. |
Tesamorelin — TES-5 / TES-20 (5mg / 20mg vials)
| Class | Stabilized GHRH analog (trans-3-hexenoic acid conjugate) |
| Reconstitution | TES-5: Add 2.5 mL BAC water → 2 mg/mL · TES-20: Add 4 mL BAC water → 5 mg/mL |
| Research Dose | 1–2 mg/day |
| Protocol | Daily SubQ; 3–6 month research cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Extended half-life vs. native GHRH. Research has examined visceral adiposity reduction and IGF-1 elevation. |
IGF-1 LR3 — IGF-1
| Class | Long-chain IGF-1 analog (83 amino acids) |
| Reconstitution | Step 1: Add 0.6% acetic acid → dissolve fully. Step 2: Dilute with BAC water to 100 mcg/mL working solution |
| Research Dose | 20–100 mcg/injection |
| Protocol | Daily or post-activity SubQ or IM; 4–6 week cycles with extended off periods |
| Route | SubQ or IM |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Acetic acid reconstitution required first — BAC water alone will not dissolve. Extended half-life (~20–30 hrs) vs. native IGF-1. |
Section 3 — Recovery & Repair
BPC-157 — BP-10 (10mg vial)
| Class | Stable gastric pentadecapeptide; 15 amino acids |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 250–500 mcg/injection |
| Protocol | 1–2x daily SubQ near target site; or oral for GI research; 4–12 week cycles |
| Route | SubQ (local or systemic), oral (GI tract), intranasal (CNS research) |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Stable in gastric acid — unique among peptides. Route selection drives tissue targeting in research models. |
TB-500 — TB-10 (10mg vial)
| Class | Thymosin Beta-4 synthetic analog |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | Loading: 2.5–7.5 mg/week · Maintenance: 2.5–5 mg biweekly |
| Protocol | Loading phase 4–6 weeks; maintenance ongoing; 2x weekly SubQ or IM |
| Route | SubQ or IM |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Actin-sequestering mechanism promotes cell migration and angiogenesis in research. Systemic distribution allows distal-site injection. |
KPV — KPV-10 (10mg vial)
| Class | Tripeptide (Lys-Pro-Val); C-terminal α-MSH fragment |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 100–500 mcg/injection SubQ; or oral for intestinal research |
| Protocol | 1–2x daily; 4–8 week cycles |
| Route | SubQ, oral (GI), intranasal |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Anti-inflammatory signaling via MC1R. Oral stability makes it unique for gut-targeted research without injection. |
LL-37 — LL-5 (5mg vial)
| Class | Human cathelicidin antimicrobial peptide; 37 amino acids |
| Reconstitution | Add 1 mL BAC water → 5,000 mcg/mL |
| Research Dose | 100–500 mcg/injection |
| Protocol | Daily SubQ; 2–4 week research cycles |
| Route | SubQ or topical (research) |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Broad-spectrum antimicrobial and immunomodulatory peptide. Research examines wound healing, biofilm disruption, and immune signaling. |
Glutathione — GLUT-600 (600mg vial)
| Class | Tripeptide antioxidant (Glu-Cys-Gly) |
| Reconstitution | Add 6 mL BAC water → 100 mg/mL |
| Research Dose | 200–600 mg/session |
| Protocol | 1–3x weekly IV push or SubQ; nebulized for pulmonary oxidative stress research |
| Route | IV (slow push), SubQ, nebulized |
| Storage | Refrigerate (2–8°C); use within 30 days — store in amber/foil-wrapped vial (light-sensitive) |
| Notes | Oral bioavailability is poor; IV and SubQ routes are the focus in research. Liposomal oral form being studied as alternative delivery. |
Section 4 — Peptide Blends
Wolverine — BPTB-10 (10mg vial)
Composition: BPC-157 5mg + TB-500 5mg
| Reconstitution | Add 2 mL BAC water → 5 mg/mL total (2,500 mcg each per mL) |
| Research Dose | 500 mcg–1 mg/injection |
| Protocol | 1–2x daily SubQ near injury site; 4–8 week cycles |
| Route | SubQ or IM |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | BPC-157 targets local repair signaling; TB-500 distributes systemically. Combined protocol studied for synergistic tissue recovery. |
GLOW — GLOW-70 (70mg vial)
Composition: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg
| Reconstitution | Add 7 mL BAC water → 10 mg/mL total |
| Research Dose | 500 mcg–2 mg/injection |
| Protocol | 3–5x weekly SubQ; 8–12 week cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Collagen remodeling (GHK-Cu) + local repair (BPC-157) + systemic recovery (TB-500). Research context: skin, connective tissue, and anti-inflammatory. |
KLOW — KLOW-80 (80mg vial)
Composition: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg
| Reconstitution | Add 8 mL BAC water → 10 mg/mL total |
| Research Dose | 500 mcg–2 mg/injection |
| Protocol | 3–5x weekly SubQ; 8–12 week cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | GLOW formula + KPV anti-inflammatory tripeptide. Research context adds gut/intestinal inflammation to the GLOW target profile. |
Section 5 — Longevity & Mitochondrial
GHK-Cu — GHK-50 (50mg vial)
| Class | Copper tripeptide (Gly-His-Lys) |
| Reconstitution | Add 5 mL BAC water → 10 mg/mL |
| Research Dose | 1–3 mg SubQ; or 1–5 mg/mL topical serum |
| Protocol | Daily to 3x weekly SubQ; 8–12 week cycles |
| Route | SubQ, topical, intranasal (neuroprotection research) |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Potent collagen synthesis and remodeling signal. Naturally declining with age — research models examine skin, hair, wound, and neurological repair. |
Epitalon — EP-10 (10mg vial)
| Class | Tetrapeptide (Ala-Glu-Asp-Gly); pineal gland peptide bioregulator |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 5–10 mg/day |
| Protocol | 10–20 day cycles; 2–3x per year; daily SubQ or IM |
| Route | SubQ or IM |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Telomerase activation is the primary research focus. Short burst cycles rather than chronic daily use reflect the research literature. |
MOTS-C — MOT-10 / MOT-20 / MOT-40 (10mg / 20mg / 40mg vials)
| Class | Mitochondrial-derived peptide (16 amino acids) |
| Reconstitution | Add 2 mL BAC water per 10mg → 5 mg/mL |
| Research Dose | 5–10 mg/injection; 2–3x weekly |
| Protocol | Ongoing; exercise-timing synergistic; morning preferred in research models |
| Route | SubQ or IM |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Encoded in mitochondrial genome. Research focuses on metabolic flexibility, insulin sensitivity, and exercise-adaptive signaling. |
Humanin — HU-10 (10mg vial)
| Class | Mitochondrial-encoded 21-amino acid peptide |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 2–10 mg/injection; 2–3x weekly |
| Protocol | Ongoing longevity protocol; 8–12 week cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Cytoprotective and anti-apoptotic in research models. Often studied alongside MOTS-C as a mitochondrial peptide stack. |
SS-31 — SS-10 (10mg vial)
| Class | Szeto-Schiller peptide; mitochondria-targeted antioxidant |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 1–5 mg/injection |
| Protocol | Daily or 3–5x weekly SubQ; 4–8 week cycles |
| Route | SubQ or IV |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Selectively concentrates in inner mitochondrial membrane. Research examines cardioprotection, neuroprotection, and oxidative stress mitigation. |
5-Amino-1MQ — 5AM-10 (10mg vial)
| Class | NNMT (nicotinamide N-methyltransferase) inhibitor |
| Reconstitution | Add 2 mL BAC water → 5 mg/mL |
| Research Dose | 50–100 mg/day (route and form per research protocol) |
| Protocol | Daily; commonly paired with NAD+ precursors in longevity stacks |
| Route | SubQ (research); also studied in oral capsule form |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | NNMT inhibition elevates intracellular NAD+ and SAM. Research examines metabolic reprogramming and epigenetic modulation. |
NAD+ — ND-500 / ND-1000 (500mg / 1000mg vials)
| Class | Nicotinamide adenine dinucleotide; coenzyme |
| Reconstitution | ND-500: Add 5 mL sterile or BAC water → 100 mg/mL · ND-1000: Add 10 mL → 100 mg/mL |
| Research Dose | 250–1,000 mg/session |
| Protocol | Weekly to 2x weekly IV infusion preferred in research; SubQ at lower doses |
| Route | IV (slow push or drip), SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days — light-sensitive; store in amber vial |
| Notes | IV route produces a “flush” sensation in many research subjects, consistent with rapid NAD+ tissue uptake. Slow infusion rate reduces discomfort. |
Section 6 — Immune & Thymic
Thymosin Alpha-1 — TA1-10 (10mg vial)
| Class | Thymic peptide; 28 amino acids |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 1.6 mg/injection; 2x weekly |
| Protocol | 6–12 month ongoing protocols studied in immune research; SubQ |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | T-cell maturation and NK cell activity are primary research endpoints. Distinguished from BPC-157 as immune-first vs. repair-first in stacking decisions. |
Thymulin — THY-10 (10mg vial)
| Class | Thymic nonapeptide; zinc-dependent hormone |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 10–50 mcg/injection |
| Protocol | 3x weekly SubQ; 4–8 week cycles |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Zinc cofactor required for biological activity. Research models examine T-cell differentiation, pain modulation, and autoimmune signaling. |
Section 7 — Sleep & Neuropeptides
DSIP — DSIP / DSIP-10 (various vials)
| Class | Delta Sleep-Inducing Peptide; 9 amino acids |
| Reconstitution | Add 1–2 mL BAC water → 1,000–2,500 mcg/mL |
| Research Dose | 25–100 mcg/injection |
| Protocol | Evening SubQ 30–60 min before sleep; 5–10 day research cycles |
| Route | SubQ or IV |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Named for delta wave sleep induction in early research. Also studied for stress modulation, ACTH normalization, and pain response in research settings. |
Section 8 — Cognitive & Mood
Selank — SEL-10 (10mg vial)
| Class | Anxiolytic heptapeptide; tuftsin analog |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 250–500 mcg/dose |
| Protocol | 1–3x daily intranasal (2–3 drops per nostril) or SubQ; 10–14 day research cycles |
| Route | Intranasal (primary), SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Anxiolytic without sedation in research models. Distinguished from Semax by mechanism: Selank modulates GABA/serotonin, Semax modulates BDNF/dopamine. |
Semax — SMX-10 (10mg vial)
| Class | ACTH(4–7) analog; nootropic neuropeptide |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 200–900 mcg/day |
| Protocol | 1–2x daily intranasal; 10–14 day on / 10–14 day off cycles |
| Route | Intranasal (primary), SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Rapid BDNF elevation is a consistent research finding. Cycled protocols are the norm to avoid habituation. |
VIP — VIP-10 (10mg vial)
| Class | Vasoactive Intestinal Peptide; 28 amino acids |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 25–100 mcg/dose |
| Protocol | 1–2x daily SubQ or intranasal; 4–8 week cycles |
| Route | SubQ, intranasal, nebulized (pulmonary research) |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Broad receptor distribution: gut, lung, immune, and CNS. Research applications span pulmonary inflammation, circadian rhythm, and neuroinflammation. |
Section 9 — Hormonal & Vitality
Kisspeptin — KISS-10 (10mg vial)
| Class | Neuropeptide; GnRH axis regulator |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 1–10 mcg/kg body weight |
| Protocol | 1–2x daily SubQ; cycled to prevent receptor desensitization |
| Route | SubQ or IV (research setting) |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Upstream regulator of LH and FSH. Research examines reproductive axis restoration, HPG reactivation, and testosterone signaling in hypogonadal models. |
Oxytocin — OXY-2 / OXY-10 (2mg / 10mg vials)
| Class | Cyclic nonapeptide; neurohypophysial hormone |
| Reconstitution | OXY-2: Add 2 mL BAC water → 1,000 mcg/mL · OXY-10: Add 5 mL BAC water → 2,000 mcg/mL |
| Research Dose | 10–40 IU intranasal (~34–136 mcg); or 0.1–0.5 mg SubQ |
| Protocol | 15–30 min pre-session; intranasal preferred for CNS delivery research |
| Route | Intranasal (primary), SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Research examines social cognition, pair bonding, anxiety reduction, and trust modulation. Nasal administration bypasses blood-brain barrier more efficiently than SubQ in research models. |
PT-141 — PT-10 (10mg vial)
| Class | Bremelanotide; melanocortin-4 receptor agonist |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 0.5–2 mg/injection |
| Protocol | 1–2 hours pre-session; as needed — maximum 2x weekly in research; not for daily use |
| Route | SubQ (primary), intranasal |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | MC4R activation drives central arousal signaling independent of vascular mechanisms. Distinguished from PDE5 inhibitors by CNS-first mechanism. |
Section 10 — Aesthetic & Pigmentation
Melanotan I — MT1-10 (10mg vial)
| Class | Afamelanotide; linear α-MSH analog; MC1R agonist |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 0.5–1 mg/day SubQ (loading); 2–3x weekly (maintenance) |
| Protocol | Daily SubQ loading until target effect; then maintenance; UV exposure studied as synergistic activator |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Linear structure provides higher MC1R selectivity than MT-II. Approved in EU for erythropoietic protoporphyria (EPP) as Scenesse implant. |
Melanotan II — MT2-10 (10mg vial)
| Class | Cyclic α-MSH analog; non-selective MC1R/MC3R/MC4R agonist |
| Reconstitution | Add 2 mL BAC water → 5,000 mcg/mL |
| Research Dose | 0.25–1 mg/injection |
| Protocol | Daily loading; 2–3x weekly maintenance; UV exposure synergistic in pigmentation research |
| Route | SubQ |
| Storage | Refrigerate (2–8°C); use within 30 days |
| Notes | Non-selective receptor profile activates MC4R (libido and appetite) in addition to MC1R (pigmentation). Distinguishing from MT-I in research: more potent, broader receptor coverage, more variable response profile. |
All information on this page is for educational and research purposes only. Not medical advice. Consult a licensed healthcare provider before beginning any protocol.